Similarly, our data in this study show inhibition of AR by Enzalutamide dramatically blocked prostate cancer cells entering S phase from G1 (Fig. 6), especially in androgen-dependent LNCaP cells. The gene discussed is AR; the disease is Familial prostate cancer.